Related Experiment Videos
[Clinical efficacy of flomoxef in the field of pediatrics]
H Ogura1, H Kubota, N Murakami
1Department of Pediatrics, Kochi Medical School.
Insights
Flomoxef sodium (FMOX) demonstrated excellent clinical efficacy in pediatric patients for various bacterial infections. This new oxacephem antibiotic proved safe and effective across all treated children.
Area of Science:
- Pediatric infectious diseases
- Antibiotic research
- Pharmacology
Background:
- Flomoxef sodium (FMOX) is a novel oxacephem antibiotic.
- Pediatric infections require effective and safe therapeutic options.
Observation:
- Nine pediatric patients (6 months to 14 years) with bacterial pneumonia, acute tonsillitis, acute enterocolitis, cellulitis, and urinary tract infections were treated.
- FMOX was administered at 57-150 mg/kg/day for 5-18 days.
Findings:
- Excellent or good clinical efficacy was achieved in all 9 cases (4 excellent, 5 good).
- The only adverse reaction noted was transient eosinophilia in one patient, which resolved upon treatment cessation.
Implications:
- Flomoxef sodium shows significant promise as a safe and effective antibiotic for pediatric bacterial infections.
- Further research may establish FMOX as a valuable addition to the pediatric infectious disease armamentarium.
Abstract:
A new oxacephem antibiotic, flomoxef sodium (FMOX, 6315-S), was studied for its clinical efficacy in the field of pediatrics. The treated patients were infants and children ranging from 6 months to 14 years old suffering from bacterial pneumonia in 3 cases, acute tonsillitis in 2 cases, acute enterocolitis in 2 cases, and cellulitis and urinary tract infection in 1 case each, a total of 9 cases. FMOX was administered at (levels of) 57-150 mg/kg in daily dose with durations of treatment ranging from 5 to 18 days. Clinical efficacies of good or excellent results were obtained in all cases (excellent in 4, good in 5). As an adverse reaction, eosinophilia was observed in 1 patient. This elevation is, however, normalized with the cessation of the treatment.